Cytomegalovirus PCR from Saliva in Minutes

Using a Digital Microfluidics Disposable Cartridge in a Near-Patient Platform This study demonstrates feasibility of CMV PCR assays from newborn saliva in a digital microfluidics (DMF) disposable cartridge to enable …

The first experience in Tuscany

Digital microfluidics (DMF), a new technology for newborn screening of Lysosomal Storage Disease A comparative study was performed in Florence Italy between our SEEKER digital microfluidics (DMF) platform and the …

Comprehensive, Near Patient Hyperbilirubinemia Testing in Newborns Using Low Blood Volume

Neonatal jaundice is a common condition that can lead to severe hyperbilirubinemia and kernicterus if not treated promptly. Comprehensive determination of hyperbilirubinemia risk requires testing for multiple analytes, including total serum bilirubin (TSB), albumin and glucose-6-phosphate dehydrogenase (G6PD), which currently are performed separately.

Comparison of Newborn Screening Platforms for Lysosomal Storage Disorders

As newborn screening (NBS) programs expand to include lysosomal storage disorders (LSDs), prospective results from active LSD screening programs can be used to compare the performance of available screening methodologies. Two FDA-cleared platforms are currently available for LSD enzyme testing from dried blood spot specimens – tandem mass spectrometry (MS/MS) and digital microfluidic fluorometry (DMF). The emerging clinical results reflect the real world performance of each platform and should be considered alongside the associated costs (equipment, maintenance, personnel, etc.) and workflow of each platform to determine the best fit for each NBS laboratory.